MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

PUMA BIOTECHNOLOGY, INC. (PBYI)

PUMA BIOTECHNOLOGY, INC. (PBYI)

|||

Balance Sheets Overview

Current Ratio
291.16%
Quick Ratio
264.42%
Cash Ratio
73.33%
Debt to Asset Ratio
28.12%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities
    • Cash and cash equivalents
    • Accounts receivable
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Lease liabilities, long-term
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
36,537
36,193
29,635
53,525
Marketable securities
57,366
65,352
67,893
40,863
Accounts receivable
34,060
26,329
53,654
33,565
Inventory
13,324
8,693
5,515
9,476
Prepaid expenses, current
3,586
3,405
3,642
3,830
Restricted cash, current
0
2,091
2,091
2,091
Other assets, current
199
196
256
230
Total current assets
145,072
142,259
162,686
143,580
Lease right-of-use assets, net
4,420
4,574
5,373
6,147
Property and equipment, net
103
124
187
305
Intangible assets, net
36,522
38,957
41,392
43,827
Restricted cash, long-term
-
-
0
0
Deferred tax assets
3,830
3,830
3,830
7,075
Prepaid expenses and other, long-term
2,789
2,955
2,834
1,928
Total assets
192,736
192,699
216,302
202,862
Accounts payable
3,105
8,166
5,056
6,386
Accrued expenses
45,130
38,378
50,031
37,116
Lease liabilities, current
450
125
1,314
2,470
Post-marketing commitment liability
1,140
1,684
2,187
2,858
Current portion of long-term debt
0
11,283
22,523
33,716
Other liabilities, current
0
101
142
182
Total current liabilities
49,825
59,737
81,253
82,728
Lease liabilities, long-term
4,367
4,546
4,709
4,866
Post-marketing commitment liability, long-term
-
-
0
0
Total long-term debt, net
-
-
0
0
Other liabilities, long-term
-
-
0
0
Total liabilities
54,192
64,283
85,962
87,594
Common stock - 0.0001 par value per share 100,000,000 shares authorized 51,102,687 shares issued and outstanding at june 30, 2026 and 50,408,023 issued and outstanding at december 31, 2025
5
5
5
5
Additional paid-in capital
1,417,923
1,415,970
1,414,074
1,412,457
Accumulated other comprehensive (loss) income
-45
-31
36
19
Accumulated deficit
-1,279,339
-1,287,528
-1,283,775
-1,297,213
Total stockholders equity
138,544
128,416
130,340
115,268
Total liabilities and stockholders equity
192,736
192,699
216,302
202,862
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$57,366K (38.69%↑ Y/Y)Cash and cashequivalents$36,537K (-33.16%↓ Y/Y)Accounts receivable$34,060K (31.46%↑ Y/Y)Inventory$13,324K (55.09%↑ Y/Y)Prepaid expenses,current$3,586K (-7.79%↓ Y/Y)Other assets, current$199K (172.60%↑ Y/Y)Total current assets$145,072K (6.22%↑ Y/Y)Intangible assets, net$36,522K (-21.05%↓ Y/Y)Lease right-of-useassets, net$4,420K (56.29%↑ Y/Y)Deferred tax assets$3,830K (-45.87%↓ Y/Y)Prepaid expenses andother, long-term$2,789K (56.25%↑ Y/Y)Property and equipment,net$103K (-73.45%↓ Y/Y)Total assets$192,736K (-1.12%↓ Y/Y)Total liabilities andstockholders equity$192,736K (-1.12%↓ Y/Y)Total stockholdersequity$138,544K (32.30%↑ Y/Y)Total liabilities$54,192K (-39.92%↓ Y/Y)Accumulated deficit-$1,279,339K (2.05%↑ Y/Y)Accumulated othercomprehensive (loss) income-$45K (-221.43%↓ Y/Y)Additional paid-in capital$1,417,923K (0.51%↑ Y/Y)Total currentliabilities$49,825K (-37.01%↓ Y/Y)Lease liabilities,long-term$4,367K Common stock - 0.0001par value per share...$5K (0.00%↑ Y/Y)Accrued expenses$45,130K (41.93%↑ Y/Y)Accounts payable$3,105K (-42.75%↓ Y/Y)Post-marketing commitmentliability$1,140K (-65.39%↓ Y/Y)Lease liabilities,current$450K (-89.69%↓ Y/Y)